More recently, PARP inhibitors have emerged as a promising class of therapeutic agents in the realm of cancer treatments for patients suffering from breast and ovarian cancer and are demonstrating valuable benefits for prostate cancer patients [9]. Here, PARP1 is linked to cancer.